Pathophysiology of RAGE in inflammatory diseases

被引:89
|
作者
Dong, Hanbing [1 ]
Zhang, Yue [1 ]
Huang, Yu [1 ]
Deng, Hui [1 ]
机构
[1] Jilin Univ, Hosp 1, Dept Neurol & Neurosci Ctr, Changchun, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
RAGE; ligands; signaling; inflammatory diseases; RAGE inhibitors; GLYCATION END-PRODUCTS; GROUP BOX 1; CELL-SURFACE-RECEPTOR; A-BETA ACCUMULATION; BLOOD-BRAIN-BARRIER; LYSOPHOSPHATIDIC ACID; S100; PROTEINS; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; OXIDATIVE STRESS;
D O I
10.3389/fimmu.2022.931473
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The receptor for advanced glycation end products (RAGE) is a non-specific multi-ligand pattern recognition receptor capable of binding to a range of structurally diverse ligands, expressed on a variety of cell types, and performing different functions. The ligand-RAGE axis can trigger a range of signaling events that are associated with diabetes and its complications, neurological disorders, cancer, inflammation and other diseases. Since RAGE is involved in the pathophysiological processes of many diseases, targeting RAGE may be an effective strategy to block RAGE signaling.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Molecular Pathophysiology of Epithelial Barrier Dysfunction in Inflammatory Bowel Diseases
    Lee, Jessica Y.
    Wasinger, Valerie C.
    Yau, Yunki Y.
    Chuang, Emil
    Yajnik, Vijay
    Leong, Rupert W. L.
    PROTEOMES, 2018, 6 (02):
  • [22] Active and passive involvement of claudins in the pathophysiology of intestinal inflammatory diseases
    Christian Barmeyer
    Michael Fromm
    Jörg-Dieter Schulzke
    Pflügers Archiv - European Journal of Physiology, 2017, 469 : 15 - 26
  • [23] Active and passive involvement of claudins in the pathophysiology of intestinal inflammatory diseases
    Barmeyer, Christian
    Fromm, Michael
    Schulzke, Joerg-Dieter
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2017, 469 (01): : 15 - 26
  • [24] A Review on Inflammatory Bowel Diseases: Recent Molecular Pathophysiology Advances
    Abdulla, Maheeba
    Mohammed, Nafeesa
    BIOLOGICS-TARGETS & THERAPY, 2022, 16 : 129 - 140
  • [25] Therapeutic Potential of Targeting the HMGB1/RAGE Axis in Inflammatory Diseases
    Singh, Harbinder
    Agrawal, Devendra K.
    MOLECULES, 2022, 27 (21):
  • [26] The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity
    Alhouayek, Mireille
    Muccioli, Giulio G.
    TRENDS IN MOLECULAR MEDICINE, 2012, 18 (10) : 615 - 625
  • [27] Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
    Onat, Altan
    Direskeneli, Haner
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (11) : 1465 - 1477
  • [28] FREE-RADICALS IN INFLAMMATORY BOWEL DISEASES PATHOPHYSIOLOGY AND THERAPEUTIC IMPLICATIONS
    GROSS, V
    ARNDT, H
    ANDUS, T
    PALITZSCH, KD
    SCHOLMERICH, J
    HEPATO-GASTROENTEROLOGY, 1994, 41 (04) : 320 - 327
  • [29] Pathophysiology and Pathogenesis of Immune-Mediated Inflammatory Diseases: Commonalities and Differences
    Rahman, Proton
    Inman, Robert D.
    El-Gabalawy, Hani
    Krause, Denis O.
    JOURNAL OF RHEUMATOLOGY, 2010, 37 : 11 - 26
  • [30] Cutaneous Manifestations in Patients With Inflammatory Bowel Diseases: Pathophysiology, Clinical Features, and Therapy
    Marzano, Angelo V.
    Borghi, Alessandro
    Stadnicki, Antoni
    Crosti, Carlo
    Cugno, Massimo
    INFLAMMATORY BOWEL DISEASES, 2014, 20 (01) : 213 - 227